| Ident. | Authors (with country if any) | Title |
|---|
| 000014 |
Nicolas Morin [Canada] ; Vincent A. Jourdain ; Thérèse Di Paolo | Modeling dyskinesia in animal models of Parkinson disease : ANIMAL MODELS OF PARKINSON'S DISEASE |
| 000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 000071 |
Philip Seeman [Canada] ; Michele Tinazzi [Italie] | Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia |
| 000095 |
Christopher Kobylecki [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia |
| 000140 |
Behzad Elahi [Canada] ; Nicolás Phielipp [Canada] ; Robert Chen [Canada] | N-Methyl-D-Aspartate Antagonists in Levodopa Induced Dyskinesia: A Meta- Analysis |
| 000199 |
Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Negre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarie [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France] | A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease |
| 000202 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
| 000216 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease |
| 000226 |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease |
| 000294 |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Ilona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Therese Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials |
| 000302 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 000306 |
Carlo Colosimo [Italie] ; Pablo Martinez-Martin [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis] | Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations |
| 000308 |
Marc Morissette [Canada] ; Pershia Samadi [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Nancy Belanger [Canada] ; Thérèse Di Paolo [Canada] | Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys |
| 000318 |
S. W. Hung [Canada, États-Unis] ; G. M. Adeli [Canada] ; T. Arenovich [Canada] ; S. H. Fox [Canada] ; A. E. Lang [Canada] | Patient perception of dyskinesia in Parkinson's disease |
| 000323 |
Daniella Rylander [Suède] ; Martin Parent [Canada] ; Sean S. O'Sullivan [Royaume-Uni] ; Sandra Dovero [France] ; Andrew J. Lees [Royaume-Uni] ; Erwan Bezard [France] ; Laurent Descarries [Canada] ; M. Angela Cenci [Suède] | Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced Dyskinesia |
| 000327 |
Galit Kleiner-Fisman [Canada] ; Andres Lozano [Canada] ; Elena Moro [Canada] ; Yu-Yan Poon [Canada] ; Anthony E. Lang [Canada] | Long-Term Effect of Unilateral Pallidotomy on Levodopa-Induced Dyskinesia |
| 000338 |
Rena K. Mann [Canada] ; Roderick Edwards [Canada] ; Julie Zhou [Canada] ; Mandar Jog [Canada] ; Christian Duval [Canada] | Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease |
| 000349 |
Renan P. Souza [Canada] ; Vincenzo De Luca [Canada] ; Gary Remington [Canada] ; Jeffrey A. Lieberman [États-Unis] ; Herbert Y. Meltzer [États-Unis] ; James L. Kennedy [Canada] ; Albert H. C. Wong [Canada] | Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia |
| 000362 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease |
| 000401 |
P.-J. Blanchet [Canada] ; B. Lalonde [Canada] ; G.-J. Lavigne [Canada] | Douleur orofaciale et désordres oromoteurs |
| 000418 |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's Disease: On Movement, Mood, and Madness |
| 000426 |
A. R. Troiano [Canada] ; R. De La Fuente-Fernandez [Canada] ; V. Sossi [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; T. J. Ruth [Canada] ; A. J. Stoessl [Canada] | PET demonstrates reduced dopamine transporter expression in PD with dyskinesias |
| 000436 |
Pershia Samadi [Canada] ; Alex Rajput [Canada] ; Frédéric Calon [Canada] ; Laurent Gregoire [Canada] ; Oleh Homykiewicz [Canada, Autriche] ; Ali H. Rajput [Canada] ; Thèrèse Di Paolo [Canada] | Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients |
| 000478 |
Vesna Sossi [Canada] ; Katherine Dinelle [Canada] ; Geoffrey J. Topping [Canada] ; James E. Holden [États-Unis] ; Doris Doudet [Canada] ; Michael Schulzer [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Raul De La Fuente-Femandez [Canada] | Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's : an in vivo imaging study |
| 000486 |
C. Warren Olanow [États-Unis] ; Jean-Michel Gracies [États-Unis] ; Christopher G. Goetz [États-Unis] ; A. Jon Stoessl [Canada] ; Thomas Freeman [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; James Godbold [États-Unis] ; Jose A. Obeso [Espagne] | Clinical Pattern and Risk Factors for Dyskinesias Following Fetal Nigral Transplantation in Parkinson's Disease : A Double Blind Video-Based Analysis |
| 000500 |
Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [États-Unis] ; Pershia Samadi [Canada] ; Paul J. Bedard [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Therese Di Paolo [Canada] | Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys |
| 000507 |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease |
| 000514 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
| 000515 |
Alison Fenney [Canada] ; Mandar S. Jog [Canada] ; Christian Duval [Canada] | Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea |
| 000521 |
Stephen J. Kish [Canada] ; JUNCHAO TONG [Canada] ; Oleh Hornykiewicz [Autriche] ; Ali Rajput [Canada] ; Li-Jan Chang [Canada] ; Mark Guttman [Canada] ; Yoshiaki Furukawa [Canada] | Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease |
| 000537 |
Jorge Guridi [Espagne] ; Jose A. Obeso [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Andres A. Lozano [Canada] ; Miguel Manrique [Espagne] ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay ; Marwan I. Hariz ; Ventura Arjona ; Jose G. Martin-Rodriguez | L-DOPA-INDUCED DYSKINESIA AND STEREOTACTIC SURGERY FOR PARKINSON'S DISEASE. Commentaries |
| 000553 |
I. Rektorova [République tchèque] ; S. Sedlackova [République tchèque] ; S. Telecka [République tchèque] ; A. Hlubocky [République tchèque] ; I. Rektor [République tchèque] | Dorsolateral Prefrontal Cortex : A Possible Target for Modulating Dyskinesias in Parkinson's Disease by Repetitive Transcranial Magnetic Stimulation |
| 000554 |
Shen-Yang Lim [Australie] ; Michael J. Farrell [Australie] ; Stephen J. Gibson [Australie] ; Robert D. Helme [Australie] ; Anthony E. Lang [Canada] ; Andrew H. Evans [Australie] | Do Dyskinesia and Pain Share Common Pathophysiological Mechanisms in Parkinson's Disease? |
| 000564 |
Alison Fenney [Canada] ; Mandar S. Jog [Canada] ; Christian Duval [Canada] | Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology |
| 000592 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
| 000599 |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
| 000632 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
| 000633 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
| 000683 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
| 000701 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
| 000703 |
R. Pahwa [États-Unis] ; S. A. Factor [États-Unis] ; K. E. Lyons [États-Unis] ; W. G. Ondo [États-Unis] ; G. Gronseth [États-Unis] ; H. Bronte-Stewart [États-Unis] ; M. Hallett [États-Unis] ; J. Miyasaki [Canada] ; J. Stevens [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000714 |
Francesca Morgante [Canada, Italie] ; Alberto J. Espay [Canada] ; Carolyn Gunraj [Canada] ; Anthony E. Lang [Canada] ; Robert Chen [Canada] | Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias |
| 000725 |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 000737 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Claude Rouillard [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Daniel Levesque [Canada] | Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys |
| 000738 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa |
| 000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000760 |
Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada] | Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease |
| 000779 |
Jonathan M. Brotchie [Canada] | Nondopaminergic mechanisms in levodopa-induced dyskinesia |
| 000785 |
Guy Chouinard [Canada] ; Howard C. Margolese [Canada] | Manual for the Extrapyramidal Symptom Rating Scale (ESRS) |
| 000800 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
| 000809 |
Véronique Sgambato-Faure [France] ; Virginie Buggia [France] ; Frangois Gilbert [Canada] ; Daniel Levesque [Canada] ; Alim-Louis Benabid [France] ; Francois Berger [France] | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-lnduced behavioral sensitization in dyskinetic rats |
| 000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
| 000838 |
J. E. Nash [Canada] ; P. Ravenscroft [Royaume-Uni] ; S. Mcguire [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; F. S. Menniti [États-Unis] ; J. M. Brotchie [Canada] | The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease |
| 000847 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000849 |
Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada] | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations |
| 000868 |
Raul De La Fuente-Fernandez [Canada] ; Vesna Sossi [Canada] ; ZHIGAO HUANG [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias |
| 000871 |
Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
| 000873 |
Frédéric Calon [Canada] ; Mehdi Dridi [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada] | Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias |
| 000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
| 000933 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada] | Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems |
| 000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 000937 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000979 |
C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis] | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's Disease |
| 000A13 |
Frédéric Calon [Canada] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias |
| 000A38 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
| 000A43 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
| 000A46 |
Ravikant S. Palur [Canada] ; Caglar Berk ; Michael Schulzer ; Christopher R. Honey | A metaanalysis comparing the results of pallidotomy performed using microelectrode recording or macroelectrode stimulation |
| 000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000A84 |
Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
| 000B13 |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
| 000B18 |
Y. R. Wu [Taïwan] ; R. Levy [Canada] ; P. Ashby [Canada] ; R. R. Tasker [Canada] ; J. O. Dostrovsky [Canada] | Does stimulation of the GPi control dyskinesia by activating inhibitory axons? |
| 000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
| 000B54 |
A. E. Lang [Canada] ; LANGSTON ; RASCOL ; BROTCHIE ; BENABID ; MELAMED ; BONUCELLI ; OLANOW ; OBESO ; GIMENEZ-ROLDAN ; RAJPUT ; FAHN ; NUTT ; BROOKS ; CHASE | Surgery for levodopa-induced dyskinesias. Discussion |
| 000B65 |
M. Filion [Canada] ; OBESO ; BENABID ; OLANOW ; LANG ; HIRSCH ; NUTT | Physiologic basis of dyskinesia. Discussion |
| 000B77 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; R. Levy [Canada] ; W. Hutchison [Canada] ; J. Dostrovsky [Canada] | Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine |
| 000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
| 000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| 000B95 |
J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada] | Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia |
| 000B97 |
Frédéric Calon [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bedard [Canada] | Dopamine-receptor stimulation : biobehavioral and biochemical consequences |
| 000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
| 000C12 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 000C13 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
| 000C22 |
V. Fraïle [Canada] ; H. Cohen [Canada] | Temporal control of voicing in Parkinson's disease and tardive dyskinesia speech |
| 000C48 |
R. A. Hauser [États-Unis] ; T. B. Freeman [États-Unis] ; B. J. Snow [Canada] ; M. Nauert [États-Unis] ; L. Gauger [États-Unis] ; J. H. Kordower [États-Unis] ; C. W. Olanow [États-Unis] | Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease |
| 000C62 |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
| 000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
| 000C69 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content |
| 000C78 |
A. Hadjtahar [Canada] ; P. J. Bedard [Canada] | Comprendre et traiter les dyskinésies induites par la levodopa |
| 000D19 |
R. Kumar [Canada] ; A. M. Lozano [Canada] ; Y. J. Kim [Canada] ; W. D. Hutchison [Canada] ; E. Sime [Canada] ; E. Halket [Canada] ; A. E. Lang [Canada] | Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson disease |
| 000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
| 000D83 |
A. Kishore [Canada] ; I. M. Turnbull [Canada] ; B. J. Snow [Canada] ; R. De La Fuente-Fernandez [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: Six-month follow-up with additional 1-year observations |
| 000E11 |
P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada] | Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients |
| 000E28 |
M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada] | Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys |
| 000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 000E36 |
R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
| 000E43 |
AGDU'L-MISSAGH GHADIRIAN [Canada] ; L. Annable ; M.-C. Belanger ; G. Chouinard | A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients |
| 000E50 |
A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
| 000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
| 000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
| 000F10 |
P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
| 000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
| 000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 001019 |
J. A. Jesberger ; J. S. Richardson | Oxygen free radicals and brain dysfunction |
| 001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
| 001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001065 |
R. T. Ross | Drug-induced Parkinsonism and other movement disorders |
| 001096 |
P. J. Bedard ; R. Boucher | Effect of D1 receptor stimulation in normal and MPTP monkeys |
| 001144 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Parkinson's disease: cognitive changes in relation to treatment response |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
